Stockscreener 앱 받기
7.90
2.46%
0.19
시간 외 거래:
8.01
0.11
+1.39%
전일 마감가:
$7.71
열려 있는:
$7.7
하루 거래량:
19,604
Relative Volume:
0.51
시가총액:
$47.26M
수익:
$43.77M
순이익/손실:
$-35.04M
주가수익비율:
-2.4292
EPS:
-3.2521
순현금흐름:
$-5.51M
1주 성능:
+1.41%
1개월 성능:
-6.62%
6개월 성능:
-32.14%
1년 성능:
-18.60%
1일 변동 폭
$7.70
$8.05
1주일 범위
$7.40
$8.66
52주 변동 폭
$6.4652
$16.52
Xilio Therapeutics Inc Stock (XLO) Company Profile
명칭
Xilio Therapeutics Inc
전화
617-833-1027
주소
828 WINTER STREET, WALTHAM
Compare XLO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
7.90 | 46.13M | 43.77M | -35.04M | -5.51M | -3.2521 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-06 | 개시 | Leerink Partners | Outperform |
| 2022-12-21 | 개시 | Chardan Capital Markets | Buy |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
| 2021-11-16 | 개시 | Cowen | Outperform |
| 2021-11-16 | 개시 | Guggenheim | Buy |
| 2021-11-16 | 개시 | Morgan Stanley | Overweight |
| 2021-11-16 | 개시 | Raymond James | Outperform |
모두보기
Xilio Therapeutics Inc 주식(XLO)의 최신 뉴스
Actuate Therapeutics Adds Oncology Expert to Board Leadership - TipRanks
Net current asset value per share of Xilio Therapeutics, Inc. – NASDAQ:XLO - TradingView
Xilio Therapeutics (XLO) price target decreased by 28.57% to 20.40 - MSN
[ARS] Xilio Therapeutics, Inc. SEC Filing - Stock Titan
Xilio Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Stock plan change and virtual 2026 annual meeting at Xilio (XLO) - Stock Titan
Xilio Therapeutics (XLO) upgraded to buy: What does it mean for the stock? - MSN
What failed trades Xilio Therapeutics (XLO)? (Slight Gain) 2026-04-27Market Expert Watchlist - Newser
XLO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Xilio Therapeutics | 8-K: Current report - Moomoo
Xilio Therapeutics (XLO) Stock: Growth Outlook (+2.63%) 2026-04-18Sector Analysis - Cổng thông tin điện tử tỉnh Lào Cai
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 - Sahm
XLO: Xilio Therapeutics Presents Promising Preclinical Findings for XTX601 at AACR - GuruFocus
Xilio announces new preclinical data for XTX601 at AACR - TipRanks
Xilio Therapeutics appoints Cheryl Blanchard to board By Investing.com - Investing.com India
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors - Sahm
Xilio Therapeutics (XLO) grants director 10,000 stock options at $8.40 - Stock Titan
Xilio Therapeutics (XLO) director Cheryl Blanchard enters as reporting insider - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Xilio Therapeutics Announces Board Changes and Committee Leadership - TipRanks
Xilio Therapeutics, Inc. Files 8-K Current Report with SEC – Company and Entity Information, April 2026 - Minichart
Xilio Therapeutics appoints Cheryl R. Blanchard as director and committee chair - Investing.com India
Xilio Therapeutics appoints Blanchard to its Board of Directors - TipRanks
Xilio Therapeutics Appoints New Board Member - Intellectia AI
Xilio Therapeutics appoints Cheryl Blanchard to board - Investing.com
Xilio Therapeutics (NASDAQ: XLO) adds Cheryl Blanchard to board roles - Stock Titan
Xilio Therapeutics, Inc. Announces Board and Committee Changes - marketscreener.com
Levels Update: Is Xilio Therapeutics Inc attractive for institutional investorsRate Hike & Risk Managed Investment Signals - baoquankhu1.vn
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting - ADVFN
Certain Series C common stock warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Pre-Funded Warrants of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Stock Options of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Certain Common Stock of Xilio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-APR-2026. - marketscreener.com
Xilio Therapeutics Inc. (XLO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
XLO Should I Buy - Intellectia AI
Energy Moves: What is the long term forecast for Xilio Therapeutics Inc stockEarnings Beat & Reliable Breakout Forecasts - baoquankhu1.vn
Surprises Report: How cyclical is Xilio Therapeutics Incs revenue streamQuarterly Investment Review & Real-Time Stock Entry Alerts - baoquankhu1.vn
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Xilio Therapeutics, Inc. (XLO) stock price, news, quote and history - Yahoo Finance UK
Xilio Therapeutics Announces Inducement Grants - National Today
Xilio Therapeutics Grants Inducement Shares Under Nasdaq Rule - National Today
Xilio Therapeutics gives 2 new hires stock options at $8.48 a share - Stock Titan
XLO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Xilio Therapeutics (XLO) Raised to Buy: How Will This Impact the Shares? - Bitget
Xilio Therapeutics (XLO) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Update Report: Does Xilio Therapeutics Inc have high return on assets2026 Rallies & Risk Controlled Stock Alerts - baoquankhu1.vn
Retail Trends: Can Xilio Therapeutics Inc deliver alphaMarket Sentiment Report & Fast Exit Strategy with Risk Control - baoquankhu1.vn
[Form 4] Xilio Therapeutics, Inc. Insider Trading Activity - Stock Titan
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares - Investing.com
Shannon James Samuel, Xilio Therapeutics director, buys $43,949 in shares By Investing.com - Investing.com India
Xilio Therapeutics Inc (XLO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):